| 2024-10-04 | +0.56 % |
|
| 2024-10-03 | -1.51 % |
|
| 2024-10-02 | -0.98 % |
|
| 2024-10-01 | -0.03 % |
|
| 2024-09-26 | +0.07 % |
|
| 2024-09-25 | -0.41 % |
|
| 2024-09-24 | -0.11 % |
|
| 2024-09-20 | -0.15 % |
|
| 2024-09-17 | -1.64 % |
|
| 2024-09-13 | |
|
| 2024-09-10 | +0.41 % |
|
| 2024-09-06 | +0.56 % |
- Medtronic (MDT) stock rose 0.56% due to increased options trading, positive quarterly earnings results that exceeded analyst expectations, and favorable upgrades in price targets from multiple equity research analysts.
- The Medtronic (MDT) stock increased by 0.56% following positive market sentiment driven by its collaboration with Orchestra BioMed, which has received a Buy rating and a favorable price target from analysts, indicating confidence in the company's innovative approaches and potential for success in product development.
- The article discusses the increasing global burden of gastrointestinal cancers, noting a rise in incidence and death rates, particularly for colorectal, pancreatic, and liver cancers from metabolic dysfunction.
Medtronic (MDT) stock likely rose by 0.56% due to positive market sentiment or investor confidence influenced by its involvement in medical technologies related to cancer treatment and management, as suggested by the mention of the company's research grants in the context of gastrointestinal cancer.
- Medtronic (MDT) stock rose by 0.56% likely due to increased investing activity from institutional investors, positive analyst upgrades on target prices, and a recent earnings report that exceeded expectations, indicating financial stability and growth potential.
|
| 2024-09-03 | +0.43 % |
|
| 2024-08-15 | +2.34 % |
|
| 2024-08-13 | +1.33 % |
|
| 2024-08-12 | -1.04 % |
|
| 2024-08-08 | +1.38 % |
|
| 2024-08-06 | +0.56 % |
|
| 2024-08-05 | -1.45 % |
|
| 2024-07-24 | +0.72 % |
|
| 2024-07-18 | -0.06 % |
|
| 2024-07-17 | +4.05 % |
- The article discusses high-yield dividend stocks, such as Medtronic (MDT), and emphasizes the importance of analyzing stocks beyond just their yield profiles to ensure they are sound investments; Medtronic's stock went up last night, likely due to its 10-year history of consecutive dividend growth, diverse line of healthcare products providing stable cash flows, strong market position, record of innovation, and a good entry point for a high-yielding stock with a strong balance sheet.
- Summary: Thoroughbred Financial Services LLC acquired a new stake in Medtronic plc (NYSE:MDT) in the 1st quarter, leading to a 4.05% increase in the company's stock price, with several other hedge funds also adding stakes in Medtronic, and research analysts providing varying ratings and target prices for the stock.
Medtronic (MDT) stock went up as Thoroughbred Financial Services LLC and several other hedge funds acquired new stakes in the company, leading to increased investor confidence and positive analyst ratings and target price revisions for the stock.
|
| 2024-07-16 | +1.32 % |
- Summary: Baird adjusted its outlook on Medtronic (MDT) by lowering its price target to $82.00 but maintained a Neutral rating, anticipating that the company's first-quarter fiscal year 2025 revenue and adjusted earnings per share (EPS) will exceed consensus expectations, driven by stable top-line growth, operational improvements, and supply chain initiatives, despite caution surrounding future EPS growth, with the stock rising 1.32% last night.
Medtronic's stock went up due to positive developments in its top-line growth, operational improvements, and supply chain initiatives that are stabilizing year-over-year operating margin compression and showing potential for margin expansion and EPS growth, despite caution by Baird surrounding the sustainability of long-term EPS growth acceleration.
- Truist Securities revised Medtronic (MDT) stock's price target to $85 from $88, maintaining a Hold rating, citing its slightly lower earnings prospects relative to industry peers and applying a 15 times multiple to the projected EPS for 2025, hinting that the stock went up due to the potential for Medtronic to demonstrate improved growth trajectory or outperform earnings expectations.
- The article discusses the importance of boards in appointing the right CEO by examining examples of poor leadership at public companies, such as Home Depot, and highlighting the need for better succession planning processes to avoid negative impacts on businesses. Medtronic (MDT) stock went up by 1.32% last night, likely due to positive market trends or company-specific news that influenced investor sentiment.
|
| 2024-07-15 | -1.12 % |
|
| 2024-07-11 | +1.31 % |
|
| 2024-07-10 | +0.23 % |
|
| 2024-07-09 | +0.05 % |
|
| 2024-06-28 | -0.78 % |
|
| 2024-06-26 | -0.45 % |
|
| 2024-06-25 | -0.78 % |
|
| 2024-06-21 | +1.83 % |
- The article discusses how the stock of Medtronic (MDT) went up by 1.83% last night, with institutional investors like Thomasville National Bank selling holdings in Medtronic and other investors buying shares, after Medtronic reported earnings beating consensus estimates, upholding a strong financial performance and outlook.
- Medtronic (MDT) stock was up 1.83% last night due to positive quarterly earnings results, where the medical technology company reported higher than expected earnings and revenue, leading to increased investor optimism and analyst ratings on the stock.
- Summary: Los Angeles Capital Management LLC significantly increased its stake in Medtronic plc (NYSE:MDT) in the first quarter, contributing to the stock's 1.83% increase. Other hedge funds and institutional investors also made changes to their positions in MDT, leading to positive market sentiment and a general positive outlook on the company's shares.
Reason for MDT stock increase: The increase in institutional investments, particularly by Los Angeles Capital Management LLC and other hedge funds, as well as positive quarterly earnings results, beating analyst estimates, contributed to the rise in Medtronic's stock price.
|
| 2024-06-20 | +0.53 % |
|
| 2024-06-18 | -0.25 % |
|
| 2024-06-14 | -0.76 % |
|
| 2024-06-12 | -1.09 % |
|
| 2024-06-11 | -1.43 % |
|
| 2024-06-10 | -1.11 % |
|
| 2024-06-07 | +2.1 % |
|
| 2024-06-06 | +0.04 % |
|
| 2024-06-05 | -1.15 % |
|
| 2024-06-04 | +1.4 % |
|
| 2024-06-03 | +0.92 % |
|
| 2024-05-31 | +0.96 % |
|
| 2024-05-30 | -1.09 % |
- The article discusses Barry McCarthy's resignation as Peloton's CEO and its impact, particularly mentioning that Medtronic (MDT) stock was down 1.09% last night. Medtronic's stock decrease could be attributed to various factors, such as market conditions, company performance, or investor sentiment.
- The article discusses Medtronic (MDT) stock, which was down 1.09% last night, with analysts offering varied ratings and price targets, and Medtronic recently reporting quarterly earnings results that beat estimates. The stock likely experienced a decline due to the mixed analyst ratings, potentially influenced by factors such as competition, market conditions, and the company's financial performance.
- The article discusses various stock upgrades, downgrades, and initiations made by different financial firms, with Goldman Sachs initiating coverage of Medtronic (MDT) with a Sell rating and $83 price target due to downside to Street earnings estimates from the need to reinvest in the business to support growth amid stable end markets and competitive industry dynamics.
|
| 2024-05-29 | -0.62 % |
- Article Summary: Medtronic plc (NYSE:MDT) is increasing its dividend to $0.70, 1.4% higher than last year, with a dividend yield of 3.4%, above industry average. The stock went down -0.62%, attributed to concerns about the sustainability of high dividend payments relative to earnings, despite healthy cash flows. Earnings per share are forecasted to rise by 66.6%, but with past declines and a high dividend payout ratio, it may not be a good income stock. Investors are advised to consider other factors beyond dividend payouts when analyzing stock performance.
Reason for Medtronic(MDT) Stock Going Down: The stock went down due to concerns about the sustainability of high dividend payments relative to earnings, despite healthy cash flows and forecasted earnings growth.
- The article reports that Medtronic (MDT) announced the pricing of senior notes, leading to a decrease of -0.62% in the stock; this drop in stock value is likely due to investor reaction to the Offering of senior notes which can impact the company's financial structure and raise concerns about increased indebtedness.
- The article discusses how BTIG adjusted its price target for Globus Medical shares after the company surpassed expectations in the first quarter of 2024, resulting in its stock performing well while Alphatec's stock experienced a drop. Medtronic (MDT) stock might have gone down due to investors reevaluating their expectations after the contrasting reactions in the market to the earnings reports of different players in the Spine sector, with particular attention given to Globus Medical's strong performance.
|
| 2024-05-28 | -0.35 % |
|
| 2024-05-24 | +1.12 % |
|
| 2024-05-23 | -5.11 % |
- The article discusses how Medtronic (MDT) finished their fiscal year strongly with growth across various segments and new product cycles entering high-growth markets, leading to optimism for the future; however, last night their stock was down by -5.11%. The reason for the stock decline is not explicitly mentioned in the article.
- Summary: The article discusses Medtronic's financial performance in the fiscal year 2024 fourth quarter, highlighting the company's overall strong revenue growth across its different segments and its focus on innovation and new product launches. However, despite positive performance indicators, Medtronic's stock experienced a decline of -5.11% last night.
Reason for Medtronic (MDT) Stock Decline: The decline in Medtronic's stock could be attributed to various factors, such as market conditions, profit-taking by investors, concerns over future growth prospects, or reactions to specific financial announcements made by the company during the earnings call.
- The article discusses how Nvidia's strong quarterly results led to a surge in tech stocks, including a 10% increase in Nvidia's stock price, but resulted in declines in blue-chip stocks like Medtronic (MDT), which was down 5.11% due to broader market caution related to growing inflation concerns.
|
| 2024-05-22 | +0.69 % |
- The article discusses the rise in Medtronic (MDT) stock by 0.69% last night, attributing this increase to the competitiveness of the market for PFA catheters, with companies like Boston Scientific, Medtronic, and Johnson & Johnson investing in this technology, potentially leading to lower prices in the future to attract more users and gain market share.
- Medtronic's stock increased by 0.69% last night, with a recent analysis focusing on the company's weak fundamentals, particularly its Return on Equity (ROE) of 8.1%, lower than the industry average of 11%, indicating a five-year net income decline possibly due to lower ROE. The company's high payout ratio of 87% has led to shrinking earnings, but future expectations suggest an improvement with a drop in the payout ratio to 52% and an expected rise in ROE to 14%. An analyst forecasts page offers insights into expectations for the company's earnings growth rate despite its current performance.
- The article discusses Orchestra BioMed Holdings, Inc.'s announcement about participating in the Jefferies Global Healthcare Conference, which led to Medtronic (MDT) stock going up by 0.69% the previous night. Medtronic's stock may have increased due to the positive developments and strategic collaborations mentioned in the article.
|
| 2024-05-21 | +0.78 % |
- The article discusses the recent increase of 0.78% in Medtronic (MDT) stock and highlights that PNC Financial Services Group Inc. reduced its holdings in Medtronic by 13.8% during the 4th quarter, leading to other institutional investors buying shares in the company, while several research firms have issued ratings and target prices for MDT stock, with the latest earnings report showing positive results. The stock price increase could be attributed to the positive analyst ratings, strong earnings report, and institutional interest in the company.
- Medtronic (MDT) stock was up 0.78% last night, with expectations that the company will benefit from increased procedures volume and expansion of new products, leading to potential growth due to valuation metrics and positive organic sales growth projections, despite recent underperformance compared to the S&P 500.
- The article suggests that healthcare stocks, including Medtronic (MDT), have strong potential for growth in the upcoming months and years, with Medtronic's stock recently experiencing a 0.78% increase likely due to positive market sentiment surrounding healthcare stocks amidst current economic conditions.
|
| 2024-05-20 | -1.64 % |
- Summary: Dexcom, a leader in continuous glucose monitoring for diabetes, launched Dexcom ONE+ and published the Dexcom State of Type 2 Report, revealing struggles faced by those with Type 2 diabetes and the benefits of real-time CGM usage, impacting Medtronic stock.
Reason for Medtronic (MDT) stock decline: The launch of Dexcom ONE+ by Dexcom, offering an improved CGM system for diabetes management and highlighting the benefits of real-time glucose monitoring, may have impacted Medtronic stock negatively due to potential competition and market perception of Dexcom's advancements in the field.
- The article discusses how the Sphere-9 Catheter by Medtronic plc showed favorable safety and efficacy in treating patients with irregular heartbeats, specifically atrial fibrillation (AFib); however, despite positive study findings, Medtronic (MDT) stock was down 1.45% likely due to various market factors or broader trends impacting the stock price movement.
- The article discusses Boeing's ongoing crisis and the re-election of CEO Dave Calhoun to the company's board despite shareholder dissatisfaction, with a focus on a need for new leadership with technical expertise in aerospace technology. Medtronic (MDT) stock went down because former Medtronic CEO Bill George, an executive fellow at Harvard Business School, stated that Boeing needs a new CEO with a technical background and deep understanding of aerospace technology for the company to regain credibility and make bold changes.
|
| 2024-05-17 | +0.33 % |
|
| 2024-05-16 | +1.09 % |
|
| 2024-05-15 | +0.5 % |
|
| 2024-05-14 | +0.93 % |
|
| 2024-05-13 | +0.82 % |
|
| 2024-05-10 | +0.1 % |
|
| 2024-05-09 | +1.48 % |
|
| 2024-05-07 | +0.17 % |
|
| 2024-05-06 | +0.09 % |
|
| 2024-05-03 | +0.95 % |
|
| 2024-05-02 | +0.04 % |
|
| 2024-05-01 | +0.81 % |
|
| 2024-04-30 | -0.77 % |
|
| 2024-04-29 | +1.4 % |
- The article discusses how Medtronic (MDT) stock rose by 1.4% as Kovack Advisors Inc. increased its stake in the company, and other large investors also modified their holdings, leading to positive market sentiment and analyst ratings, along with stable financial performance and dividend payouts.
- The article provides a comparison of Orchestra BioMed and its competitors in the "Surgical & medical instruments" industry, highlighting factors such as volatility, revenue, earnings, valuation, and institutional ownership, with Orchestra BioMed showing a higher price-to-earnings ratio and strong consensus rating from research analysts leading to a potential upside. Medtronic(MDT) stock may have gone up due to positive outlook on Orchestra BioMed's products and collaborations with companies like Medtronic.
- The article discusses how Medtronic (MDT) stock was up by 1.4% last night, and the possible reason for this increase could be due to positive market sentiment, company performance, or news related to Medtronic.
|
| 2024-04-26 | +0.62 % |
- Medtronic (MDT) stock went up by 0.62% last night following the announcement of FDA approval for their Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain due to its innovative closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, providing personalized and effective relief for patients without compromising future access to MRI.
- The article discusses Orchestra BioMed (NASDAQ:OBIO) and compares it to its competitors in the surgical and medical instruments industry, highlighting its strong profitability and potential upside. Medtronic (MDT) stock went up due to its collaboration agreement with Orchestra BioMed for the development and commercialization of BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN).
- The article discusses Orchestra BioMed (NASDAQ:OBIO) and compares it to its competitors in the surgical and medical instruments industry, highlighting factors such as valuation, volatility, revenue, earnings, and institutional ownership. While Orchestra BioMed's competitors have higher revenue and earnings, it is trading at a higher price-to-earnings ratio, indicating it is more expensive. Medtronic (MDT) stock went up by 0.62% likely due to the positive performance of Orchestra BioMed, a company it collaborates with, particularly in the development and commercialization of products such as BackBeat Cardiac Neuromodulation Therapy for hypertension (HTN) and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease.
|
| 2024-04-25 | -1.41 % |
|
| 2024-04-24 | -1.12 % |
|
| 2024-04-23 | +0.89 % |
|
| 2024-04-18 | +0.14 % |
|
| 2024-04-16 | -1.22 % |
- The article discusses how the stock of various companies, including Salesforce, Gamestop, JP Morgan Chase, and Medtronic (MDT), has been moving. Last night, Medtronic's stock was down by -1.22%, breaking below previous support levels and potentially signaling weakness in the stock. This drop in Medtronic's stock price may be attributed to a lack of buyer interest at previous price levels, leading to selling pressure and causing the stock to decline further.
- The article discusses the medical device company Medtronic (MDT) and mentions that the stock was down by -1.22% last night. Medtronic's stock may have gone down due to challenges in the hospital market post-COVID, where capital budgets and purchasing have been restricted, prompting the company to seek partners to increase the penetration of its products.
|
| 2024-04-12 | -2.48 % |
|
| 2024-04-11 | -0.19 % |
|
| 2024-04-10 | -1.75 % |
|
| 2024-04-09 | +1.07 % |
|
| 2024-04-08 | -1.95 % |
|
